• Cytokinetics President and CEO Robert I. Blum sold 7,500 common shares at $62.81 each on November 2, 2026.
• Blum exercised non-qualified stock options for 7,500 common shares at $10.6 each that same day.
• Direct common stock holdings stood at 278,544 shares following the transactions; remaining non-qualified stock options totaled 134,245.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000107), on November 02, 2026, and is solely responsible for the information contained therein.